Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytoreductive surgery with or without HIPEC using cisplatin for peritoneal carcinomatosis from ovarian, fallopian tube, or primary peritoneal carcinoma
2011-001715-31Phase 3Terminated
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoint: Disease-free survival. Started Sep 2011; status: terminated.
02
Drugs
cisplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2011-001715-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001715-31.